Skip to main content
. 2022 May 5;7(7):1463–1476. doi: 10.1016/j.ekir.2022.04.094

Figure 1.

Figure 1

Proposed algorithm for SGLT2 inhibitor initiation. ∗Consider earlier bloodwork in higher risk: stage ≥3B CKD, prior episode(s) of acute kidney injury, or at risk for volume depletion. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; MRA, mineralocorticoid receptor antagonist.